Medtronic Receives the US FDA’s Approval for Pipeline Flex Embolization Device with Shield Technology

 Medtronic Receives the US FDA’s Approval for Pipeline Flex Embolization Device with Shield Technology

Medtronic Receives the US FDA’s Approval for Pipeline Flex Embolization Device with Shield Technology

Shots:

  • The US FDA has approved Pipeline Flex Embolization Device with a Shield Technology to advance flow diversion therapy that demonstrates a reduction in material thrombogenicity or a reduction in the tendency of the surface treatment material to create clots
  • The first patient receives new shield surface modification at NYU Langone Health. The SHIELD study evaluates the safety and efficacy of third-generation pipeline embolization device with shield technology for intracranial aneurysms
  • The SHIELD study results showed 77.2% complete aneurysm occlusion @12 mos., 3.2% primary safety endpoint, and 93.1% complete wall apposition post-procedure

Click here to­ read full press release/ article | Ref: Medtronic | Image: Seeking Alpha

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post